Long non‑coding RNAs lnc‑ANGPTL1‑3:3 and lnc‑GJA10‑12:1 present as regulators of sentinel lymph node metastasis in breast cancer

Sun, Desheng; Zhong, Jieyu; Wei, Wei; Liu, Li; Li, Jun; Lin, Xiaona

doi:10.3892/ol.2020.12050

Cited by 11 publications

(12 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of the miRNA-mRNA network from multiple studies reveals that miR-34a-5P, with the cooperation of speci c proteins, plays a role in breast cancer and other gynecological cancers as well (48-50). As an example, hsa-miR-34a-5p was discovered in two separate studies published in 2017 and 2020 as a potential marker of metastasis (51,52) and chemo-resistance (53,54) (55). This research reported a negative correlation between miR-501-3p and its target genes, suggesting that this miRNA could be a new candidate for TNBC targeted therapies.…”

Section: Discussionmentioning

confidence: 91%

The transcriptomic data of about 5,000 breast tumors reveals novel biomarkers

Rahmati

Davarinejad

Mohammadi

et al. 2022

Preprint

View full text Add to dashboard Cite

The high mortality rate in Breast Cancer (BC) is largely due to the difficulty of early detection and inadequate accuracy of the current diagnostic approaches. MicroRNAs (miRNAs) are a class of non-coding RNAs characterized by their short length of 22 nucleotides-length, which have been found with regulatory functions in gene expression and their dysregulation are associated with a wide variety of human diseases such as various types of cancer including BC. In this study, we investigated serum and tumor miRNA profiles from more than 1500 breast cancer miRNA expression profiles from GEO and also more than 2500 patients by TCGA database. After data analysis by some packages like Limma, MetaDE, and WGCNA, we selected 6 hub miRNAs. Then by collecting serum samples of 100 breast cancer patients, real-time PCR was performed and the diagnosis performance of hub miRNAs was evaluated by ROC curve. Due to more validation, Kaplan-Meier Plot of hub miRNAs evaluated by 1262 BC samples using METABRIC database. Therefore by considering internationally and locally data, we succeeded to identify the more prevalent and effective breast cancer biomarkers including Hsa-miR-151a-5p, Hsa-miR-34a-5p, Hsa-miR-1307-3p, Hsa-miR-450b-5p, Hsa-miR-501-3p, and Hsa-miR-532-5p.

show abstract

Section: Discussionmentioning

confidence: 91%

The transcriptomic data of about 5,000 breast tumors reveals novel biomarkers

Rahmati

Davarinejad

Mohammadi

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…In addition, hepatocellular carcinoma (HCC) [ 29 ], pancreatic cancer [ 30 ], and other cancers have become significant prognostic markers. The gap junction α (GJA) family has been demonstrated to be involved in the cellular proliferation and metastasis of gastric cancer and breast cancer [ 31 , 32 ]. In the current study, we found that CYSLTR2 [ 33 , 34 ], CYP4Z1 [ 35 ], LINC00324 [ 36 ], and PTCSC3 [ 37 ] have shown a close relationship with the initiation and development of tumors and also with the prognosis of the COAD patients.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of Colorectal Cancer Immunity and Identification of Immune-Related Prognostic Targets

Wen

Bukhari

et al. 2022

Disease Markers

View full text Add to dashboard Cite

Colorectal cancer (COAD) is ranked as the third most common cancer and second in terms of cancer-related deaths worldwide. Due to its poor overall survival and prognosis, the incidents of COAD are significantly increasing. Although treatment methods have greatly been improved in the last decade, it is still not good enough to have satisfactory treatment outcomes. In recent years, immunotherapy has been successful to some extent in the treatment of many cancers but still, many patients do not respond to immunotherapy. Therefore, it is essential to have a deeper understanding of the immune characteristics of the tumor microenvironment and identify meaningful immune targets. In terms of immune targets, COAD has been poorly explored; thus, in the current study, based on the immune cell infiltration score and differentially expressed genes, COAD tumors were classified into hot and cold tumors. The Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis was used to identify hub genes, construct a prognostic model, and screen potential immune targets. In total, 12 genes (CLK3, CYSLTR2, GJA10, CYP4Z1, FAM185A, LINC00324, EEF1A1P34, EEF1B2P8, PTCSC3, MIR6780A, LINC01666, and RNU6.661P) differentially expressed between hot and cold tumors were screened out. Among them, CYSLTR2 was considered as a potential candidate gene, because it showed a significant positive correlation with immune cell infiltration and immune checkpoints (PDCD1, CD274, and CTLA4). Finally, we constructed and validated a new prognostic model for COAD showing 0.854 AUC for the ROC curve, and these results provide sufficient potential to choose CYSLTR2 as an important immune target for the prognosis of COAD.

show abstract

“…LncRNAs regulate cell progression through targeting miRNAs or mRNA (Gutschner and Diederichs, 2012;Paraskevopoulou and Hatzigeorgiou, 2016). More and more evidence shows that lncRNAs can be used as important molecular markers involved in gene regulation and cell progression (Sun et al, 2020). Mini-chromosome maintenance complex component 2 (MCM2) gene is a major gene affecting the stability of micro mitotic chromosomes Ⅲ, and MCM2 protein is a family member that initiates DNA replication and maintains progression in the cell cycle (Gottesman et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

LncRNA RP11-59J16.2 aggravates apoptosis and increases tau phosphorylation by targeting MCM2 in AD

Guan

Gao

Dai³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a degenerative disease of central nervous system with unclear pathogenesis, accounting for 60%–70% of dementia cases. Long noncoding RNAs (LncRNAs) play an important function in the development of AD. This study aims to explore the role of differentially expressed lncRNAs in AD patients’ serum in the pathogenesis of AD. Microarray analysis was performed in the serum of AD patients and healthy controls to establish lncRNAs and mRNAs expression profiles. GO analysis and KEGG pathway analysis revealed that G1/S transition of mitotic cell cycle might be involved in the development of AD. The result showed that RP11-59J16.2 was up-regulated and MCM2 was down-regulated in serum of AD patients. SH-SY5Y cells were treated with Aβ 1–42 to establish AD cell model. Dual luciferase reporter gene analysis verified that RP11-59J16.2 could directly interact with 3′UTR of MCM2 and further regulate the expression of MCM2. Inhibition of RP11-59J16.2 or overexpression of MCM2, CCK-8 assay and Annexin V FITC/PI apoptosis assay kit results showed that RP11-59J16.2 could reduce cell viability, aggravate apoptosis and increase Tau phosphorylation in AD cell model by inhibiting MCM2. In short, our study revealed a novel lncRNA RP11-59J16.2 that could promote neuronal apoptosis and increase Tau phosphorylation by regulating MCM2 in AD model, and indicated that lncRNA RP11-59J16.2 might be a potential target molecule for AD development.

show abstract

Long non‑coding RNAs lnc‑ANGPTL1‑3:3 and lnc‑GJA10‑12:1 present as regulators of sentinel lymph node metastasis in breast cancer

Cited by 11 publications

References 41 publications

The transcriptomic data of about 5,000 breast tumors reveals novel biomarkers

The transcriptomic data of about 5,000 breast tumors reveals novel biomarkers

Comprehensive Analysis of Colorectal Cancer Immunity and Identification of Immune-Related Prognostic Targets

LncRNA RP11-59J16.2 aggravates apoptosis and increases tau phosphorylation by targeting MCM2 in AD

Contact Info

Product

Resources

About